Abstract
Metformin may decrease cell senescence, including bone; hence we aimed at evaluating the association between metformin use and osteoporosis. This was a cross-sectional study carried out in 1259 Latin American adult women aged 40 or more who were not on anti-osteoporotic drugs, were on metformin and had a bone densitometry performed. Of the whole sample, 40.3% reported being on metformin (at least 1 year), 30.2% had type 2 diabetes mellitus and 22.6% had osteoporosis. Median (interquartile range) body mass index (BMI) for the whole cohort was 27.7 (4.6) kg/m2 and 30.2% had type 2 diabetes mellitus. Current use of hormone therapy, calcium, and vitamin D corresponded respectively to 10.7%, 47.7%, and 43.1% of all surveyed women. A logistic regression model was used to analyze the association of osteoporosis with various covariates incorporated into the model such as age (OR: 1.07, 95% CI: 1.05–1.09), BMI (OR: 0.92, 95% CI: 0.89–0.96) and metformin use (OR: 0.44, 95% CI: 0.32–0.59). Metformin use, regardless of the presence of type 2 diabetes or obesity, was associated with a lower risk of osteoporosis in adult women. We propose that one explanation for this observation could be the effect of the drug over cellular senescence.
摘要:
二甲双胍可减少细胞衰老, 包括骨骼;因此, 我们旨在评估应用二甲双胍与骨质疏松症之间的关系。这是一项横断面研究, 研究人群是年龄在40岁或40岁以上的1259名拉丁美洲成年女性, 她们均服用二甲双胍, 并没有服用过抗骨质疏松药物, 都进行了骨密度测定。在全部样本中, 40.3%的患者服用过二甲双胍(至少一年), 30.2%的患者患有2型糖尿病, 22.6%的患者患有骨质疏松症。整个队列的体重指数(BMI)中位数(四分位间距)为27.7(4.6)kg/m2, 30.2%患有2型糖尿病。目前激素治疗、钙和维生素D的使用率分别为10.7%、47.7%和43.1%。采用logistic回归模型分析骨质疏松症与年龄(OR:1.07, 95%CI:1.05-1.09)、体重指数(OR:0.92, 95%CI:0.89-0.96)和应用二甲双胍(OR:0.44, 95%CI:0.32-0.59)等各种协变量的关系。无论患者是否存在2型糖尿病或肥胖, 应用二甲双胍与成年女性骨质疏松低风险相关。我们认为原因可能是二甲双胍可以减少细胞衰老。
The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.
Keywords:
Acknowledgments
The authors would like to thank women who participated in this initiative.
Disclosure statement
The authors report no potential conflicts of interest.